{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zandbergen IM"],"funding":["ZonMw"],"pagination":["653"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8465768"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["<h4>Background</h4>First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%. Therefore, many patients require prolonged DA treatment, while side effects negatively impact health-related quality of life (HRQoL). Endoscopic transsphenoidal resection is reserved for patients with severe side effects, or with DA-resistant prolactinoma. Surgery has a good safety profile and high probability of remission and may thus deserve a more prominent place in prolactinoma treatment. The hypothesis for this study is that early or upfront surgical resection is superior to DA treatment both in terms of HRQoL and remission rate in patients with a no"],"journal":["Trials"],"pubmed_title":["The PRolaCT studies - a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma."],"pmcid":["PMC8465768"],"funding_grant_id":["843002806"],"pubmed_authors":["Biermasz NR","van Bon AC","Feelders RA","Nieuwlaat WCM","Burhani B","van den Akker-van Marle ME","Pelsma ICM","van de Ven AC","de Graaf JP","Kapiteijn KK","van Furth WR","Dutch Prolactinoma Study Group","Hoogmoed J","Zandbergen IM","Drent ML","le Cessie S","Pereira AM","Wakelkamp IMMJ","Zamanipoor Najafabadi AH","Dekkers OM","Bisschop PHLT","Boogaarts HDJ","Stades AME","van der Klauw MM"],"additional_accession":[]},"is_claimable":false,"name":"The PRolaCT studies - a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma.","description":"<h4>Background</h4>First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%. Therefore, many patients require prolonged DA treatment, while side effects negatively impact health-related quality of life (HRQoL). Endoscopic transsphenoidal resection is reserved for patients with severe side effects, or with DA-resistant prolactinoma. Surgery has a good safety profile and high probability of remission and may thus deserve a more prominent place in prolactinoma treatment. The hypothesis for this study is that early or upfront surgical resection is superior to DA treatment both in terms of HRQoL and remission rate in patients with a no","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2026-05-08T05:41:03.962Z","creation":"2022-02-11T11:35:51.394Z"},"accession":"S-EPMC8465768","cross_references":{"pubmed":["34563236"],"doi":["10.1186/s13063-021-05604-y"]}}